Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases
Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases. The company is addressing fibro-inflammation by targeting the TGFβ/ALK5 (TGFβR1) pathway, with a clinical pipeline that includes ontunisertib (AGMB-129) for Fibrostenosing Crohn’s Disease and AGMB-447 for Idiopathic Pulmonary Fibrosis.